A review in the journal Lupus examines treatments for primary and secondary thromboprophylaxis in patients with anti-phospholipid autoantibodies (aPL) and a history of thrombosis, which can affect more than 50 percent of people with systemic lupus erythematosus.
In a review that examines the use of conventional and orphan autoantibodies as biomarkers for diagnosing systemic lupus erythematosus (SLE), researchers say the science is advancing rapidly with the goal of diagnosing lupus earlier than currently done.
Total hip arthroplasty does not provide a clinically significant improvement over hemiarthroplasty in function and quality of life over 24 months, shows a NEJM study. The incidence of secondary procedures did not differ significantly between the two groups.
Vedolizumab proves to be superior to adalimumab for in achieving clinical remission and endoscopic improvement for ulcerative colitis, but not corticosteroid-free clinical remission.
Ustekinumab (Stelara, Janssen Biotech) was more effective at one year than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis, NEJM study shows.
Rheumatology Network is conducting a state of the practice survey for physicians and healthcare professionals who treat rheumatology patients. We'd like your feedback on issues and stressors that you and your patients face, such as the cost of healthcare to being overloaded with patients. Please take a moment to answer this multiple choice survey of just 15 questions.
The Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain. Learn more in this slideshow.
The American Society for Bone and Mineral Research has developed a set of treatment recommendations for the prevention of secondary fracture in patients 65 years and older who have had a hip or vertebral fracture. There are 13 recommendations. In this slideshow, we highlight the recommendations beginning with improved doctor-patient communication.
Ixekizumab was superior to adalimumab at 24 weeks in a head-to-head trial evaluating both skin and joint symptoms in patients with psoriatic arthritis and inadequate response to csDMARDs, say researchers writing in Annals of the Rheumatic Diseases last month.
The American Society for Bone and Mineral Research has developed clinical recommendations for the prevention of secondary fractures for patients aged 65 years and older after an initial hip or vertebral fracture. The recommendations were published in the Journal of Bone and Mineral Research last month.